Treatment for Neoplasms, Lung

Phase-Based Progress Estimates
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, NC
Neoplasms, Lung+6 More
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a mobile medical application can be used to monitor PROs in patients with lung cancer.

See full description

Eligible Conditions

  • Neoplasms, Lung
  • Pulmonary Cancer
  • Lung Cancers
  • Malignant Lung Neoplasm
  • Pulmonary Neoplasms

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 10 secondary outcomes in patients with Neoplasms, Lung. Measurement will happen over the course of From time of enrollment through last contact (6 months)/date of death, whichever came first.

2 year
Health care utilization (Emergency Department)
Health care utilization (hospitalization)
2 years
Progression Free Survival
Provider satisfaction
Recurrence free survival
6 months
Health-related quality of life (QLQ-C30)
Health-related quality of life (QLQ-LC13)
At 6 months
Feasibility of self-reporting symptoms by lung cancer patients using Moovcare®
Month 6
Overall survival
Moovcare enrollment through the end of study participation (6months)
Survey completion
Month 6
Patient satisfaction

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

This trial requires 42 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 2 year for reporting.

Closest Location

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill - Chapel Hill, NC

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Neoplasms, Lung or one of the other 6 conditions listed above. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
18 years or older
Diagnosis of lung cancer (any histology, any stage) undergoing outpatient treatment and/or surveillance/monitoring at UNC.
This may include stage I and II patients who have completed lung resection and/or are undergoing radiation, stage II and III patients receiving neoadjuvant, adjuvant, or definitive chemotherapy, stage IV patients undergoing active therapy or monitoring, patients undergoing surveillance for treated or untreated stage I-III lung cancer, and both limited and extensive small cell lung cancer. The study team will request the confirmation of the lung cancer diagnosis from the managing clinician. Patients can be enrolled at any point in their lung cancer treatment trajectory (i.e., not just at initiation of first-line treatment) after a diagnosis of lung cancer has been assigned by the treating clinician. This may include patients assigned a diagnosis of lung cancer without a tissue diagnosis.
Speaks and understands English
Reliable access to the internet and email
Access to a mobile phone (or device that can receive text messages for registration)

Patient Q&A Section

How serious can lung cancer be?

"Lung cancer is relatively rare compared to other cancers; however, the mortality is high. It remains unclear how great the risk of death from lung cancer is relative to other cancers. Current evidence suggests that most people diagnosed with lung cancer will die within five years, although some fail to respond to chemotherapy. This implies that the average survival time from diagnosis to death is around one year." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of lung cancer?

"Results from a recent paper of our study do not support the claim that cigarette smoking causes lung cancer. In fact, we found that the risk of developing lung cancer was lower among smokers than non-smokers. We conclude that cigarette smoking is unlikely to be a major factor in the development of lung cancer in North Carolina." - Anonymous Online Contributor

Unverified Answer

Has treatment proven to be more effective than a placebo?

"Recent findings suggest that a multimodality approach may be associated with improved survival compared with a standard approach for advanced nonsmall cell lung cancer. However, larger prospective studies are needed to confirm these findings." - Anonymous Online Contributor

Unverified Answer

Does lung cancer run in families?

"While there is strong evidence from epidemiological studies that smoking affects lung cancer risk substantially, we find no precedent from epidemiological studies to suggest a "hereditary" model of lung cancer susceptibility. In fact, the familial clustering observed in a recent study is even stronger than any observed in the general population, reinforcing the lack of support for an "hereditary" model of lung cancer susceptibility." - Anonymous Online Contributor

Unverified Answer

What are the chances of developing lung cancer?

"The incidence rate of lung cancer seems higher in men than women. The most common age group for lung cancer in India is between 50-59 years old. The lifetime risk of developing lung cancer is 1%. Host factors such as smoking, exposure to asbestos and environmental factors such as passive smoke and air pollution are associated with lung cancer development." - Anonymous Online Contributor

Unverified Answer

What is treatment?

"Current therapies provide undefined benefit to patients with advanced lung cancer. Physicians should be cautious about prescribing palliative care for their patients with advanced lung cancer." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of treatment?

"Patients undergoing chemotherapy experienced fatigue, nausea, vomiting, diarrhea, constipation, anemia, neutropenia, thrombocytopenia, leukopenia, fever, and rash; they had no changes in triglycerides or cholesterol levels or hepatic toxicity. Patients undergoing RT had gastrointestinal problems, leukopenia, thrombocytopenia, and congestion. There were no changes in triglycerides or cholesterol levels or hepatic toxicity. Patients receiving EGFR TKIs experienced fatigue, constipation, nausea, vomiting, diarrhea, dizziness, insomnia, peripheral edema, dyspnea, and weakness." - Anonymous Online Contributor

Unverified Answer

Is treatment typically used in combination with any other treatments?

"Typically, surgical resection is combined with adjuvant chemotherapy for lung cancer. For patients with primary non-small cell lung carcinoma, adjuvant chemotherapy improves survival compared to surgery alone." - Anonymous Online Contributor

Unverified Answer

Can lung cancer be cured?

"The cure rate varies widely across institutions. Some patients may benefit from additional therapy while others may not need further treatment after surgery and/or chemotherapy. The timing of intervention should be tailored to each patient's specific clinical presentation." - Anonymous Online Contributor

Unverified Answer

How many people get lung cancer a year in the United States?

"There's a huge variation in lung cancer incidence rates across the country. For example, the annual lung cancer incidence rate was 1.9 per 100,000 person-years in New Jersey and 10.5 in Florida. As such, it seems important to examine trends in lung cancer incidence across the US in order to better understand geographic disparities in lung cancer mortality. Although the data are limited in their scope, they suggest that higher socioeconomic status may be associated with increased lung cancer incidence. However, because no clear trend emerged, further studies will be required to confirm these findings." - Anonymous Online Contributor

Unverified Answer

Is treatment safe for people?

"People who receive concurrent chemotherapy and anti-angiogenic treatment had an increased risk of toxicity compared with those receiving only anti-angiogenic therapy. Treatment should therefore be carefully considered before starting a new anticancer treatment regimen in patients with metastatic disease who are already receiving anti-angiogenic therapy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Neoplasms, Lung by sharing your contact details with the study coordinator.